Targeting the world's first social implementation of a tooth regeneration therapy, the company is conducting research and development of an antibody drug for cases of congenital edentulism, a condition that occurs in about 0.1% of the population and is characterized by the absence of six or more permanent teeth

Given the potential application for third tooth regeneration, the company seeks to provide a new treatment option in addition to denture and implant therapy

The company is promoting multiple research projects in the field of dentistry, proposing radical treatments for cases that cannot be handled by existing treatments